Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer.

Blumenthal GM, Bunn PA Jr, Chaft JE, McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, Aisner DL, Bergh J, Berry DA, Jarkowski A, Botwood N, Cross DAE, Diehn M, Drezner NL, Doebele RC, Blakely CM, Eberhardt WEE, Felip E, Gianni L, Keller SP, Leavey PJ, Malik S, Pignatti F, Prowell TM, Redman MW, Rizvi NA, Rosell R, Rusch V, de Ruysscher D, Schwartz LH, Sridhara R, Stahel RA, Swisher S, Taube JM, Travis WD, Keegan P, Wiens JR, Wistuba II, Wynes MW, Hirsch FR, Kris MG.

J Thorac Oncol. 2018 Dec;13(12):1818-1831. doi: 10.1016/j.jtho.2018.09.017. Epub 2018 Sep 27. Review.

PMID:
30268698
2.

Neoadjuvant therapy for resectable non-small cell lung cancer with mediastinal lymph node involvement.

Tieu BH, Sanborn RE, Thomas CR Jr.

Thorac Surg Clin. 2008 Nov;18(4):403-15. doi: 10.1016/j.thorsurg.2008.07.004. Review.

PMID:
19086609
3.

Induction or neoadjuvant therapy in resectable non-small cell lung cancer.

Langer CJ.

Semin Oncol. 1999 Oct;26(5 Suppl 15):34-9. Review.

PMID:
10566609
4.

Drug development: neoadjuvant opportunities in breast cancer.

Rastogi P, Geyer CE, Mamounas EP, DeMichele A.

Am Soc Clin Oncol Educ Book. 2013:73-9. doi: 10.1200/EdBook_AM.2013.33.73.

5.

Neoadjuvant chemotherapy for resectable non-small-cell lung cancer.

Gray J, Sommers E, Alvelo-Rivera M, Robinson L, Bepler G.

Oncology (Williston Park). 2009 Sep;23(10):879-86. Review.

6.
7.

The role of induction therapy for resectable non-small cell lung cancer.

Stinchcombe TE, Socinski MA.

Drugs. 2007;67(3):321-32. Review.

PMID:
17335293
8.

Neoadjuvant chemotherapy for resectable non-small cell lung cancer.

Finkelstein EJ, Urschel JD, Takita H.

J Exp Clin Cancer Res. 1997 Dec;16(4):437-9.

PMID:
9505221
9.

[Neoadjuvant chemoradiation in non-small cell lung cancer].

Milleron B, Girard N, Gounant V, Mornex F.

Cancer Radiother. 2007 Jan-Feb;11(1-2):36-40. Epub 2006 Oct 19. Review. French.

PMID:
17055314
10.

Current readings: Window-of-opportunity trials for thoracic malignancies.

Tsao AS.

Semin Thorac Cardiovasc Surg. 2014 Winter;26(4):323-30. doi: 10.1053/j.semtcvs.2014.12.005. Epub 2014 Dec 24. Review.

PMID:
25837547
11.

Pathologic Stage of Nonsmall Cell Lung Cancer Patients Presenting as Resectable Cases After Neoadjuvant Therapy Did Not Predict the Prognosis.

Wu CY, Fu JY, Wu CF, Liu YH, Hsieh MJ, Wu YC, Yang CT, Tsai YH.

Medicine (Baltimore). 2015 Oct;94(40):e1700. doi: 10.1097/MD.0000000000001700. Erratum in: Medicine (Baltimore). 2015 Oct;94(43):1.

12.

Risk of pneumonectomy after induction therapy for locally advanced non-small cell lung cancer.

d'Amato TA, Ashrafi AS, Schuchert MJ, Alshehab DS, Seely AJ, Shamji FM, Maziak DE, Sundaresan SR, Ferson PF, Luketich JD, Landreneau RJ.

Ann Thorac Surg. 2009 Oct;88(4):1079-85. doi: 10.1016/j.athoracsur.2009.06.025.

PMID:
19766784
13.

Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum.

Glynne-Jones R, Hava N, Goh V, Bosompem S, Bridgewater J, Chau I, Gaya A, Wasan H, Moran B, Melcher L, MacDonald A, Osborne M, Beare S, Jitlal M, Lopes A, Hall M, West N, Quirke P, Wong WL, Harrison M; Bacchus investigators.

BMC Cancer. 2015 Oct 23;15:764. doi: 10.1186/s12885-015-1764-1.

14.

Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages.

Gillen S, Schuster T, Meyer Zum B├╝schenfelde C, Friess H, Kleeff J.

PLoS Med. 2010 Apr 20;7(4):e1000267. doi: 10.1371/journal.pmed.1000267. Review.

15.
16.

Adjuvant or neoadjuvant chemotherapy in minimal N2 stage IIIA nonsmall cell lung cancer.

De Craene S, Surmont V, van Meerbeeck JP.

Curr Opin Oncol. 2010 Mar;22(2):102-11.

PMID:
20180283
17.

Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial).

Kocher F, Pircher A, Mohn-Staudner A, Romeder F, Duller W, Steinmaurer M, Eckmayr J, Schmid T, Hilbe W, Fiegl M, Greil R.

Lung Cancer. 2014 Sep;85(3):395-400. doi: 10.1016/j.lungcan.2014.06.019. Epub 2014 Jul 3.

PMID:
25043642
18.

Chemotherapy in stage I+II non-small cell lung cancer.

Ukena D.

Lung Cancer. 2001 Sep;33 Suppl 1:S25-8. Review.

PMID:
11576704
19.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
20.

Neoadjuvant chemotherapy in the treatment of nonsmall-cell lung cancer.

De Pauw R, van Meerbeeck JP.

Curr Opin Oncol. 2007 Mar;19(2):92-7. Review.

PMID:
17272979

Supplemental Content

Support Center